

Francesco Fabbri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6168934/publications.pdf>

Version: 2024-02-01

63
papers

1,568
citations

279701

23
h-index

330025

37
g-index

63
all docs

63
docs citations

63
times ranked

2786
citing authors

#	ARTICLE	IF	CITATIONS
1	Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study. <i>Current Oncology</i> , 2022, 29, 433-438.	0.9	1
2	Cancer Stem Cells (CSCs), Circulating Tumor Cells (CTCs) and Their Interplay with Cancer Associated Fibroblasts (CAFs): A New World of Targets and Treatments. <i>Cancers</i> , 2022, 14, 2408.	1.7	15
3	Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 49.	3.5	11
4	Detection and Investigation of Extracellular Vesicles in Serum and Urine Supernatant of Prostate Cancer Patients. <i>Diagnostics</i> , 2021, 11, 466.	1.3	12
5	Case Report: Analysis of Circulating Tumor Cells in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient. <i>Frontiers in Medicine</i> , 2021, 8, 689895.	1.2	4
6	Circulating Tumor Cells as a Tool to Untangle the Breast Cancer Heterogeneity Issue. <i>Biomedicines</i> , 2021, 9, 1242.	1.4	6
7	A Specific Host/Microbial Signature of Plasma-Derived Extracellular Vesicles Is Associated to Thrombosis and Marrow Fibrosis in Polycythemia Vera. <i>Cancers</i> , 2021, 13, 4968.	1.7	0
8	Early Detection and Investigation of Extracellular Vesicles Biomarkers in Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 732900.	1.6	4
9	Obesity and Dose of Anti-cancer Therapy: Are We Sure to Be on the Right Track in the Precision Medicine Era?. <i>Frontiers in Medicine</i> , 2021, 8, 725346.	1.2	0
10	MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS-Mutated Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13357.	1.8	6
11	CNA Profiling of Single CTCs in Locally Advanced Esophageal Cancer Patients during Therapy Highlights Unexplored Molecular Pathways. <i>Cancers</i> , 2021, 13, 6369.	1.7	2
12	Obesity and Dose of Anti-cancer Therapy: Are We Sure to Be on the Right Track in the Precision Medicine Era?. <i>Frontiers in Medicine</i> , 2021, 8, 725346.	1.2	3
13	Know your enemy: Genetics, aging, exposomic and inflammation in the war against triple negative breast cancer. <i>Seminars in Cancer Biology</i> , 2020, 60, 285-293.	4.3	16
14	Single-Cell NGS-Based Analysis of Copy Number Alterations Reveals New Insights in Circulating Tumor Cells Persistence in Early-Stage Breast Cancer. <i>Cancers</i> , 2020, 12, 2490.	1.7	25
15	CDKN1A upregulation and cisplatin+pemetrexed resistance in non-small cell lung cancer cells. <i>International Journal of Oncology</i> , 2020, 56, 1574-1584.	1.4	19
16	CTCs 2020: Great Expectations or Unreasonable Dreams. <i>Cells</i> , 2019, 8, 989.	1.8	29
17	Adipocytes and microRNAs Crosstalk: A Key Tile in the Mosaic of Breast Cancer Microenvironment. <i>Cancers</i> , 2019, 11, 1451.	1.7	20
18	Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 863-871.	1.1	14

#	ARTICLE	IF	CITATIONS
19	Characterization of Tumor Cells Using a Medical Wire for Capturing Circulating Tumor Cells: A 3D Approach Based on Immunofluorescence and DNA FISH. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	4
20	Circulating Tumor Cells: Back to the Future. <i>Frontiers in Oncology</i> , 2017, 6, 275.	1.3	3
21	DNA ploidy and S-phase fraction analysis in peritoneal carcinomatosis from ovarian cancer: correlation with clinical pathological factors and response to chemotherapy. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4657-4664.	1.0	3
22	Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer. <i>Oncotarget</i> , 2017, 8, 2423-2436.	0.8	24
23	Circulating Tumor Cells in the Adenocarcinoma of the Esophagus. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1266.	1.8	13
24	CTCs in early breast cancer: A path worth taking. <i>Cancer Letters</i> , 2016, 376, 205-210.	3.2	28
25	IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia. <i>Journal of Translational Medicine</i> , 2015, 13, 229.	1.8	23
26	Epithelial Mesenchymal Transition: a double-edged sword. <i>Clinical and Translational Medicine</i> , 2015, 4, 14.	1.7	107
27	Circulating tumor cells in early breast cancer: A connection with vascular invasion. <i>Cancer Letters</i> , 2015, 367, 43-48.	3.2	34
28	CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems. <i>Bone</i> , 2014, 66, 214-222.	1.4	28
29	Circulating tumor cells and epithelial, mesenchymal and stemness markers: characterization of cell subpopulations. <i>Annals of Translational Medicine</i> , 2014, 2, 109.	0.7	84
30	Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. <i>Cancer Letters</i> , 2013, 335, 225-231.	3.2	208
31	Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines. <i>International Journal of Oncology</i> , 2013, 42, 1263-1270.	1.4	20
32	Perspectives on mTOR Inhibitors for Castration-Refractory Prostate Cancer. <i>Current Cancer Drug Targets</i> , 2012, 12, 940-949.	0.8	27
33	Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. <i>Cancer Cell International</i> , 2012, 12, 48.	1.8	19
34	Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. <i>Tumori</i> , 2012, 98, 696-701.	0.6	17
35	Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity. <i>Journal of Cellular Physiology</i> , 2012, 227, 3389-3396.	2.0	24
36	Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. <i>Tumori</i> , 2012, 98, 696-701.	0.6	6

#	ARTICLE	IF	CITATIONS
37	Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 316-326.	1.6	5
38	Activity of different anthracycline formulations in hormoneâ€refractory prostate cancer cell lines: Role of golgi apparatus. <i>Journal of Cellular Physiology</i> , 2011, 226, 3035-3042.	2.0	7
39	Abstract 5167: A new panel of tissue markers for the prediction of bone metastatization from primary breast cancer. , 2011, , .		0
40	Abstract 4901: Preliminary investigation of circulating NSCLC cells using dielectrophoresis-based instrumentation. , 2011, , .		0
41	Docetaxelâ€ST1481 sequence exerts a potent cytotoxic activity on hormoneâ€resistant prostate cancer cells by reducing drug resistanceâ€related gene expression. <i>Prostate</i> , 2010, 70, 219-227.	1.2	10
42	Tyrosine Kinase Inhibitors Gefitinib, Lapatinib and Sorafenib Induce Rapid Functional Alterations in Breast Cancer Cells. <i>Current Cancer Drug Targets</i> , 2010, 10, 422-431.	0.8	19
43	Role of RAF/MEK/ERK pathway, pâ€STATâ€3 and Mclâ€1 in sorafenib activity in human pancreatic cancer cell lines. <i>Journal of Cellular Physiology</i> , 2009, 220, 214-221.	2.0	69
44	Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines. <i>Anti-Cancer Drugs</i> , 2009, 20, 918-925.	0.7	12
45	Mitotic catastrophe and apoptosis induced by docetaxel in hormoneâ€refractory prostate cancer cells. <i>Journal of Cellular Physiology</i> , 2008, 217, 494-501.	2.0	51
46	Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. <i>Journal of Translational Medicine</i> , 2008, 6, 43.	1.8	24
47	NCX 4040, an NO-donating acetylsalicylic acid derivative: Efficacy and mechanisms of action in cancer cells. <i>Nitric Oxide - Biology and Chemistry</i> , 2008, 19, 225-236.	1.2	27
48	Role of p53 Codon 72 Arginine Allele in Cell Survival in vitro and in the Clinical Outcome of Patients with Advanced Breast Cancer. <i>Tumor Biology</i> , 2008, 29, 145-151.	0.8	19
49	Phase I Study of Paclitaxel and Uracil plus Tegafur Combination in Patients with Pretreated Metastatic Breast Cancer: Drug Sequencing Based on Preclinical Modelling Studies. <i>Oncology</i> , 2007, 72, 118-124.	0.9	8
50	Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines. <i>Journal of Translational Medicine</i> , 2007, 5, 52.	1.8	19
51	Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics. <i>Journal of Cellular Physiology</i> , 2007, 212, 710-716.	2.0	11
52	Short Interfering RNA Directed against the SLUG Gene Increases Cell Death Induction in Human Melanoma Cell Lines Exposed to Cisplatin and Fotemustine. <i>Analytical Cellular Pathology</i> , 2007, 29, 279-287.	0.7	15
53	Sequential events of apoptosis involving docetaxel, a microtubule-interfering agent: a cytometric study. <i>BMC Cell Biology</i> , 2006, 7, 6.	3.0	60
54	Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines*. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2006, 11, 1321-1330.	2.2	33

#	ARTICLE	IF	CITATIONS
55	p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. <i>Journal of Cellular Physiology</i> , 2006, 206, 611-615.	2.0	66
56	Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 919-926.	1.9	43
57	Cellular Basis of Antiproliferative and Antitumor Activity of the Novel Camptothecin Derivative, Gimatecan, in Bladder Carcinoma Models. <i>Neoplasia</i> , 2005, 7, 152-161.	2.3	16
58	Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2005, 10, 1095-1103.	2.2	35
59	Development and characterization of a monoclonal antibody directed against human telomerase reverse transcriptase (hTERT). <i>Journal of Biotechnology</i> , 2005, 118, 370-378.	1.9	9
60	In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines. <i>Journal of Translational Medicine</i> , 2005, 3, 7.	1.8	33
61	Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. <i>Breast Cancer Research</i> , 2005, 7, R681-9.	2.2	63
62	Schedule-Dependent Cytotoxic Interaction between Epi-doxorubicin and Gemcitabine in Human Bladder Cancer Cells in Vitro. <i>Clinical Cancer Research</i> , 2004, 10, 1500-1507.	3.2	25
63	Drosophila vitelline membrane cross-linking requires the fs(1)Nasrat, fs(1)polehole and chorion genes activities. <i>Development Genes and Evolution</i> , 2001, 211, 573-580.	0.4	30